98
13
10
↑98
↓13
—10
Evidence suggests Melatonin mayincreaseImmune function.
137 studies (121 claims)
Strong consensus
Typical effective dose 5 (3.5–17.5) mgacross 11 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| Knockout of melatonin receptor type 1A (MT1) | Decreases - more severely affected | cardiac function | Animal | aging mice | — | Melatonin alleviates aging-related heart failure through melatonin receptor 1A/B knockout in mice. |
| melatonin | No effect - inability to improve | cardiac function | Animal | aging mice lacking MT1/2 | — | Melatonin alleviates aging-related heart failure through melatonin receptor 1A/B knockout in mice. |
| intraperitoneal administration of melatonin (20 mg/kg/day for 90 days) | Decreases - ameliorated | abnormal cardiac function | Animal | aging mice | — | Melatonin alleviates aging-related heart failure through melatonin receptor 1A/B knockout in mice. |
| melatonin administration | Increases - improved | cardiac function | Animal | mice exposed to MI/R injury | — | Activation of melatonin receptor 2 but not melatonin receptor 1 mediates melatonin-conferred cardioprotection against myocardial ischemia/reperfusion injury. |
| melatonin administration | Increases - significantly more effective than donanemab, lecanemab, aducanumab and placebo | cognitive function | Human | people with mild AD and MCI | — | Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.cited 5× |
| melatonin | Increases - significantly more effective than donanemab, lecanemab, aducanumab and placebo | cognitive function | Human | people with mild AD and MCI | — | Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.cited 5× |
| melatonin receptor mutations | No effect - altered | receptor function | Human | — | — | Identification of pathway-biased and deleterious melatonin receptor mutants in autism spectrum disorders and in the general population. |
| oral melatonin supplementation | Increases - noted adverse events relating to | cardiovascular function | Human | humans | Not specified in the abstract. | Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence.cited 89× |
| oral melatonin supplementation | Increases - noted adverse events relating to | endocrine function | Human | humans | Not specified in the abstract. | Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence.cited 89× |
| melatonin (3 mg/day, 7 days) | No effect - did not differ | abnormal hepatic function | Human | elderly patients after acute heart failure | — | Effects of Melatonin for Delirium in Elderly Acute Heart Failure Patients: A Randomized, Single-Center, Double-Blind, and Placebo-Controlled Trial.cited 12× |
| melatonin | No effect - impact on | alcohol intoxication in terms of mental disorders, sleep and inflammation, hepatic injury, and mitochondrial function | Human | — | Not specified | Alcohol and melatonin.cited 14× |
| melatonin | No effect - exerts these protection effects through | anti-oxidant, anti-apoptosis, anti-inflammatory, and mitochondrial function | Human | — | Not specified | The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review.cited 64× |
| melatonin | Increases - has shown | antioxidant function | Human | — | Not specified | From Implantation to Birth: Insight into Molecular Melatonin Functions. |
| melatonin | Increases - has shown | antioxidant function | Human | — | Not specified | From Implantation to Birth: Insight into Molecular Melatonin Functions. |
| Melatonin | Increases - improved | beta-cell function | Human | T2D MTNR1B variant carriers | — | Circadian, Sleep and Caloric Intake Phenotyping in Type 2 Diabetes Patients With Rare Melatonin Receptor 2 Mutations and Controls: A Pilot Study. |
| Melatonin | Increases - improved | beta-cell function | Human | Patients with rare MTNR1B variants | — | Circadian, Sleep and Caloric Intake Phenotyping in Type 2 Diabetes Patients With Rare Melatonin Receptor 2 Mutations and Controls: A Pilot Study. |
| melatonin | Increases - ameliorating action | bladder function | Human | — | Not specified | Role of circadian rhythms and melatonin in bladder function in heath and diseases.cited 10× |
| melatonin | Affects - has a diurnal impact on | blood-glucose-regulating function | HumanAnimal | islet | Not specified | Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. |
| melatonin | Affects - has a diurnal impact on | blood-glucose-regulating function | HumanAnimal | islet | Not specified | Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. |
| melatonin | No effect - has a diurnal impact | blood-glucose-regulating function of the islet | HumanAnimalMolecular | — | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | No effect - has a diurnal impact | blood-glucose-regulating function of the islet | HumanAnimalMolecular | — | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | No effect - provides an endogenous synchronizer, modulating | blood pressure, body temperature, cortisol rhythm, sleep-awake-cycle, immune function and anti-oxidative defence | Human | humans | Not specified in the abstract. | The analgesic effects of exogenous melatonin in humans.cited 13× |
| melatonin | No effect - test the efficacy on | brain function | Human | — | 25 mg oral melatonin nightly. | Feasibility of 3-month melatonin supplementation for brain oxidative stress and sleep in mild cognitive impairment: protocol for a randomised, placebo-controlled study.cited 7× |
| melatonin | Increases - normalization of | Ca(2+) dependent and independent contraction, mitochondrial polarity, neuromuscular function and oxidative stress | Human | old animals | Not specified | Melatonin, a potential therapeutic agent for smooth muscle-related pathological conditions and aging.cited 36× |
| melatonin (MEL) | Increases - improved | cardiac function | Animal | rats | — | The vascular influence of melatonin on endothelial response to angiotensin II in diabetic rat aorta. |
| melatonin | No effect - was influenced by | cardioprotective function for MIRI | Human | patients with myocardial ischemia-reperfusion injury (MIRI) | — | Evaluation of Melatonin Therapy in Patients with Myocardial Ischemia-Reperfusion Injury: A Systematic Review and Meta-Analysis.cited 9× |
| melatonin therapy | No effect - had no significant effects on | cardiac function (left ventricular ejection fraction [LVEF], left ventricular end-diastolic volume [LVEDV], and left ventricular end-systolic volume [LVESV]) and myocardial infarct parameters (total left ventricular mass and infarct size) | Human | patients with myocardial ischemia-reperfusion injury (MIRI) | — | Evaluation of Melatonin Therapy in Patients with Myocardial Ischemia-Reperfusion Injury: A Systematic Review and Meta-Analysis.cited 9× |
| Melatonin | Affects - modulate | cardiovascular system function | Human | — | — | Expression of Melatonin Receptor 1 in Rat Mesenteric Artery and Perivascular Adipose Tissue and Vasoactive Action of Melatonin. |
| Melatonin | Increases - improved | endothelial function | Human | patients with hypertension | — | Expression of Melatonin Receptor 1 in Rat Mesenteric Artery and Perivascular Adipose Tissue and Vasoactive Action of Melatonin. |
| Melatonin | Increases - improved | endothelial function | Human | patients with coronary artery disease | — | Expression of Melatonin Receptor 1 in Rat Mesenteric Artery and Perivascular Adipose Tissue and Vasoactive Action of Melatonin. |
| Melatonin | Increases - improved | endothelial function | Human | patients with heart failure | — | Expression of Melatonin Receptor 1 in Rat Mesenteric Artery and Perivascular Adipose Tissue and Vasoactive Action of Melatonin. |
| melatonin | No effect - may play an intriguing role in direct regulation of | CL function | HumanMolecular | — | — | "Hormone of darkness" and human reproductive process: direct regulatory role of melatonin in human corpus luteum. |
| melatonin | No effect - could become a relevant medication for improving | ovarian and luteal function | HumanMolecular | — | — | "Hormone of darkness" and human reproductive process: direct regulatory role of melatonin in human corpus luteum. |
| Melatonin | No effect - no significant effect | cognitive function | Human | human participants | — | Nociceptive responses in melatonin MT |
| melatonin (10 mg/kg) | Increases - improved | cognitive function | Animal | AD-like mouse model (C57BL/6 mice) | 10 mg/kg, administered intraperitoneally. | Improving effects of melatonin on memory and synaptic potentiation in a mouse model of Alzheimer's-like disease: the involvement of glutamate homeostasis and mGluRs receptors. |
| melatonin (10 mg/kg) (early intervention) | Increases - yielded superior outcomes | cognitive function | Animal | AD-like mouse model (C57BL/6 mice) | 10 mg/kg, administered intraperitoneally. | Improving effects of melatonin on memory and synaptic potentiation in a mouse model of Alzheimer's-like disease: the involvement of glutamate homeostasis and mGluRs receptors. |
| melatonin | No effect - cognitive function is measured by | cognitive function | Human | Acutely hospitalised patients aged 65 years or older admitted for surgical repair of hip fracture | 3 mg melatonin orally at 21:00 h for five consecutive days. | The effects of melatonin versus placebo on delirium in hip fracture patients: study protocol of a randomised, placebo-controlled, double blind trial.cited 45× |
| melatonin | Increases - induced improvements | cognitive function | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin | Increases - induced improvements | motor function | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| exogenous melatonin | Increases - positive effects | motor function | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin agonists | Increases - induced improvements | cognitive function | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin agonists | Increases - positive effects | motor function | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin agonists | Increases - induced improvements | motor function | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin | Increases - cognitive enhancement | cognitive function | Human | — | Not specified | The role of melatonin in targeting cell signaling pathways in neurodegeneration.cited 38× |
| melatonin | Increases - improve | cognitive function | Human | — | Not specified | Food Functional Factors in Alzheimer's Disease Intervention: Current Research Progress.cited 1× |
| melatonin | Increases - improved | cognitive function | Human | hemodialysis patients | 3 mg daily melatonin. | Role of Melatonin as an Adjunctive Treatment for Depression and Cognitive Impairment in Hemodialysis Patients: A Randomized, Double-Blind Clinical Trial. |
| melatonin | Increases - improved | cognitive function | Animal | CHP mice | — | Melatonin attenuated the brain damage and cognitive impairment partially through MT2 melatonin receptor in mice with chronic cerebral hypoperfusion. |
| melatonin | Increases - enhanced | cognitive function | Human | human participants | — | Differential Function of Melatonin MT |
| melatonin | No effect - could affect | developing infants' sleep-wake cycle and cardiovascular function | Human | developing infants | Not specified | Effects of intrauterine growth restriction on sleep and the cardiovascular system: The use of melatonin as a potential therapy?cited 19× |
| melatonin | No effect - can orchestrate | differentiation and function of immune cells | Human | — | Not specified | Melatonin in food allergy: Mechanism and potential therapy.cited 7× |
| melatonin | Increases - suggested to boost | electron transfer system function | Human | — | Not specified | Feeding mitochondria: Potential role of nutritional components to improve critical illness convalescence.cited 86× |
| melatonin | Increases - protective effects | erectile function | Animal | type 1 diabetic rat models | 10 mg/kg (frequency not specified). | Melatonin prevents deterioration of erectile function in streptozotocin-induced diabetic rats via sirtuin-1 expression.cited 6× |
| melatonin | Increases - improved | executive function on TMT scores | Human | women with breast cancer | 20mg of melatonin before and during the first cycle of chemotherapy. | Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial.cited 69× |
| melatonin | No effect - improvement varied | function and behavior | Human | — | Not specified | Pharmacologic Treatments for Sleep Disorders in Children: A Systematic Review.cited 25× |
| melatonin | No effect - affects | function of secretase | Human | — | Not specified | Melatonin regulates Aβ production/clearance balance and Aβ neurotoxicity: A potential therapeutic molecule for Alzheimer's disease.cited 135× |
| melatonin treatment | Increases - has a promising effect on improving | cognitive function | Human | AD patients | Not specified | Melatonin regulates Aβ production/clearance balance and Aβ neurotoxicity: A potential therapeutic molecule for Alzheimer's disease.cited 135× |
| melatonin | Increases - acts as a hormone with local paracrine actions to modulate | GI function and the release of other hormones | Human | intestine | Pharmacological doses (specific amounts not provided) | Detection of melatonin production from the intestinal epithelium using electrochemical methods.cited 16× |
| melatonin | Increases - has a beneficial effect on | gut barrier function | Human | — | Not specified. | Gut microbiota in neurological diseases: Melatonin plays an important regulatory role.cited 17× |
| melatonin | Decreases - might also decrement | hepatic function parameters | Human | NAFLD patients | Not specified | The effects of melatonin therapy on the treatment of patients with Non-alcoholic steatohepatitis: A systematic review and Meta-analysis on clinical trial studies.cited 8× |
| melatonin | Increases - improve | immune cell function | Human | — | Not specified. | A mid‑pandemic night's dream: Melatonin, from harbinger of anti‑inflammation to mitochondrial savior in acute and long COVID‑19 (Review).cited 5× |
| melatonin | No effect - has immunomodulatory properties | immune function | Human | — | Not specified | Role of melatonin in periodontal disease - A systematic review.cited 12× |
| melatonin | No effect - influence | immune function | HumanMolecular | — | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| melatonin | Increases - immuno-enhancing nature | immune function | Human | — | Not specified | Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders.cited 50× |
| melatonin | Affects - is involved in the regulation of | immune function | Human | null | Not specified | Melatonin: An important anticancer agent in colorectal cancer.cited 24× |
| Melatonin | No effect - has immunomodulation properties | immune function | Molecular | — | Not specified | Melatonin and its ubiquitous anticancer effects. |
| Melatonin | No effect - has immunomodulation properties | immune function | Molecular | — | Not specified | Melatonin and its ubiquitous anticancer effects. |
| melatonin | Increases - regulated | immune function | Animal | tropical rodents | — | Melatonin membrane receptor type MT1 modulates cell-mediated immunity in the seasonally breeding tropical rodent Funambulus pennanti. |
| melatonin | No effect - regulates | immune function | Human | humans | — | No title available |
| Melatonin | Increases - enhancing | intercellular barrier function within the testes | Animal | male dairy goats under HS | Not specified | Melatonin alleviates heat stress-induced spermatogenesis dysfunction in male dairy goats by regulating arachidonic acid metabolism mediated by remodeling the gut microbiota.cited 1× |
| melatonin | No effect - modulates intestinal immune function | intestinal immune function | Molecular | — | Not specified. | Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammation.cited 108× |
| melatonin | No effect - is indirectly connected to | kidney function and quality of life | Human | people with chronic kidney disease | Not specified | Melatonin Treatment in Kidney Diseases.cited 15× |
| melatonin | Increases - improved | left-ventricular function | Human | — | Not specified | Roles of melatonin and its receptors in cardiac ischemia-reperfusion injury.cited 23× |
| melatonin | Increases - therapeutic interventions specifically aimed at improving | levels and function of HDL and PON1 | Human | — | Not specified | The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders.cited 39× |
| melatonin | No effect - no significant changes | lung function (spirometry) | Human | patients with clinically stable moderate to very severe COPD | 3mg melatonin daily. | Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study.cited 59× |
| melatonin | Decreases - gene abnormalities that could contribute to decreased melatonin production or adversely affect melatonin receptor function | melatonin production or melatonin receptor function | Human | a small percentage of children with ASD | Not specified | Melatonin in autism spectrum disorders: a systematic review and meta-analysis.cited 243× |
| melatonin | No effect - did not reduce | memory function | Human | — | Not specified | Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials.cited 70× |
| melatonin | No effect - acts as an anti-oxidant and as a regulator of mitochondrial bioenergetic function | mitochondrial bioenergetic function | Human | — | Not specified | Melatonin: A Potential Anti-Oxidant Therapeutic Agent for Mitochondrial Dysfunctions and Related Disorders.cited 52× |
| melatonin | Increases - improves | mitochondrial function | Human | diabetic patients | Not specified | New insights into the role of melatonin in diabetic cardiomyopathy.cited 14× |
| melatonin | Increases - preserving | mitochondrial function | Molecular | cardiac cells | Not specified | Insight into the cardioprotective effects of melatonin: shining a spotlight on intercellular Sirt signaling communication.cited 1× |
| melatonin | Increases - improves | mitochondrial function | Human | critically ill patients | Not mentioned | Oxidative stress in sepsis: Pathophysiological implications justifying antioxidant co-therapy.cited 159× |
| Melatonin | No effect - protective effects | mitochondrial function | Human | — | Not specified | Melatonin in septic shock: some recent concepts.cited 64× |
| melatonin | Increases - have a significant protective effect | mitochondrial function | Human | — | 50-100 mg/day (proposed for future clinical trials). | Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies.cited 68× |
| melatonin | Increases - exerts a beneficial effect on mitochondrial function to mitigate ferroptosis | mitochondrial function | AnimalMolecular | ST cells | — | Melatonin regulates mitochondrial function to alleviate ferroptosis through the MT2/Akt signaling pathway in swine testicular cells. |
| melatonin | Decreases - can be successfully used for prevention of neurodegeneration and preservation of motor function | neurodegeneration and motor function | Animal | rats | Not specified | Inhibition of cysteine proteases in acute and chronic spinal cord injury.cited 40× |
| melatonin | Increases - improving | neurological function | Animal | rats | — | Melatonin alleviates early brain injury by inhibiting the NRF2-mediated ferroptosis pathway after subarachnoid hemorrhage. |
| melatonin | Increases - may help protect | organ function | Human | — | — | Melatonin: A window into the organ-protective effects of sepsis.cited 14× |
| melatonin | Increases - leading to the preservation | ovarian function | HumanMolecular | — | Not specified | Interaction of Melatonin and BMP-6 in Ovarian Steroidogenesis.cited 17× |
| melatonin | Increases - protective effect | ovarian function | Animal | mouse model | — | Melatonin Attenuates Cyclophosphamide-Induced Primordial Follicle Loss by Interaction with MT |
| melatonin | No effect - remained stable | renal and liver function parameters | Human | 27 older adults with insomnia complaints and low endogenous melatonin levels | 0.4mg (low-dose) and 4.0mg (high-dose), both as 25% immediate-release and 75% controlled-release formulations. | Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults.cited 75× |
| melatonin | Increases - has therapeutic mechanisms including | restoring mitochondrial function | Human | — | Not specified | The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease.cited 38× |
| Melatonin | Increases - cooperates with BIX 02189 to enhance | secretion function of existing M2 macrophages | AnimalMolecular | RAW 264.7 macrophages | — | Melatonin enhances the ability of M2 macrophages to secrete IL10 by inhibiting Erk5 signaling pathway. |
| Melatonin (Mel) | Decreases - dose-dependent pattern of ameliorating | SR-induced impairments of cognitive function | Animal | — | Dose-dependent pattern of Mel (specific amounts not stated) | Melatonin Mitigates Sleep Restriction-Induced Cognitive and Glymphatic Dysfunction Via Aquaporin-4 Polarization. |
| melatonin | Increases - enhancement of | survival and function of nucleus pulposus cells | Human | — | Not specified | Melatonin: Evolving Physiological Understanding and Potential Therapeutic Role in Pain Medicine Including Intervertebral Disc Degeneration.cited 1× |
| melatonin | Increases - restoring | the function of SERCA2 | Molecular | in vitro retinal pigment epithelium (RPE) death model | — | Melatonin protects RPE cells from necroptosis and NLRP3 activation via promoting SERCA2-related intracellular Ca |
| Melatonin | Increases - has been effectively used to restore | tissue function | Human | human trials | Not specified | Melatonin as an antioxidant: under promises but over delivers.cited 1,080× |
| melatonin | No effect - suggests an influence of | vasa vasorum function and signal transduction in the aorta wall | HumanAnimal | — | — | The presence and localization of melatonin receptors in the rat aorta. |
| Melatonin | Increases - may improve | vascular function | Human | — | Not specified | Melatonin supplementation does not alter vascular function or oxidative stress in healthy normotensive adults on a high sodium diet.cited 1× |
| melatonin supplementation during a HSD | Increases - would improve | vascular function | Human | — | Not specified | Melatonin supplementation does not alter vascular function or oxidative stress in healthy normotensive adults on a high sodium diet.cited 1× |
| melatonin | Increases - may increase | β-cell function | Human | — | — | The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal?cited 7× |
| melatonin signal | No effect - depend also on | immune function | Human | — | Not specified (mentions "physiological" dose matching nocturnal peak levels). | Melatonin: Physiological effects in humans.cited 353× |
| melatonin (Mel) co-administration | Increases - exerted anti-contractile and pro-relaxation responses | vascular function in aortic rings | AnimalMolecular | male adult rats treated with nicotine | 2% RF, 2% RUF, or 4% Mel co-administered with nicotine (5 mg/kg body weight/day). RF pre-treatment in AECs: 0.015 mg/ml. | Rooibos (Aspalathus linearis) protects against nicotineinduced vascular injury and oxidative stress in Wistar rats.cited 5× |
| Pretreatment with melatonin (10 mg/kg) | Decreases - Reduction in | impaired mitochondrial function | Animal | prediabetic obese rats | — | Therapeutic potential of a single-dose melatonin in the attenuation of cardiac ischemia/reperfusion injury in prediabetic obese rats. |
| hypothermia plus melatonin | No effect - no differences | Gross Motor Function Classification System | Human | newborns | 5 mg per kg body weight, administered intravenously daily for 3 days. | Hypothermia Plus Melatonin in Asphyctic Newborns: A Randomized-Controlled Pilot Study.cited 31× |
| melatonin produced in the placenta | Increases - may preserve | the optimal function of this organ | Molecular | placenta | Not specified | Melatonin and the circadian system: contributions to successful female reproduction.cited 149× |
| melatonin treatment | Increases - preserved | cardiac function | Animal | Streptozotocin-induced diabetic Sprague-Dawley rats and high-glucose medium-incubated H9c2 cardiomyoblasts | — | Melatonin protects diabetic heart against ischemia-reperfusion injury, role of membrane receptor-dependent cGMP-PKG activation. |
| melatonin treatment | Increases - improved | CL function | Animal | sows | — | Melatonergic systems of AANAT, melatonin, and its receptor MT2 in the corpus luteum are essential for reproductive success in mammals†. |
| melatonin (MEL) treatment | Decreases - alleviated | liver function | Molecular | animals | Dose <100 μM (specific frequency not mentioned). | Melatonin intervention to prevent nanomaterial exposure-induced damages: A systematic review and meta-analysis of in vitro and in vivo studies. |
| melatonin and MSC | Increases - improving | renal function | Animal | rats with ischemia-reperfusion injury | Not specified | The Effect of Adipose Tissue Mesenchymal Stem Cells and Melatonin in a Rat Model of Renal Ischemia Reperfusion Injury.cited 1× |
| combined bright light and melatonin treatment | Decreases - improved | subjective daytime sleepiness, fatigue, and cognitive function | Human | — | Not specified for dim light (placebo). | A randomized controlled trial with bright light and melatonin for the treatment of delayed sleep phase disorder: effects on subjective and objective sleepiness and cognitive function.cited 59× |
| Nuclear receptors (ROR, RZR etc.) of melatonin | No effect - might be indirectly controlling | immune function | HumanAnimal | — | — | Photoimmunomodulation and melatonin. |
| melatonin supplementation | Increases - significantly increased | expression of genes related to mitochondrial function | Animal | porcine embryos | — | Melatonin reduces two-cell block via nonreceptor pathway in mice. |
| melatonin supplementation | Increases - significantly increased | expression of genes related to mitochondrial function | Animal | porcine embryos | — | Melatonin reduces two-cell block via nonreceptor pathway in mice. |
| melatonin supplementation | Increases - enhanced | pancreatic β-cell function | Human | patients with type 2 diabetes | Not available | Molecular Mechanisms of the Melatonin Receptor Pathway Linking Circadian Rhythm to Type 2 Diabetes Mellitus. |
| melatonin supplementation | Increases - enhanced | pancreatic β-cell function | Human | patients with type 2 diabetes | Not available | Molecular Mechanisms of the Melatonin Receptor Pathway Linking Circadian Rhythm to Type 2 Diabetes Mellitus. |
| melatonin supplementation | No effect - secondary outcomes include changes in | renal function indicators | Human | — | 5 mg melatonin tablets twice daily. | Effects of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: study protocol for a double-blind, randomized controlled trial.cited 1× |
| triple therapy involving mitochondrial transplantation, mitoquinone, and melatonin | Increases - improved | mitochondrial function | Animal | aged IR rats | Administered intraperitoneally at the onset of reperfusion (exact dosage not specified) | Mitochondrial transplantation combined with mitoquinone and melatonin: A survival strategy against myocardial reperfusion injury in aged rats. |
| triple therapy involving mitochondrial transplantation, mitoquinone, and melatonin | Increases - improving | mitochondrial function and biogenesis | Animal | aged rat hearts | Administered intraperitoneally at the onset of reperfusion (exact dosage not specified) | Mitochondrial transplantation combined with mitoquinone and melatonin: A survival strategy against myocardial reperfusion injury in aged rats. |
| triple therapy involving mitochondrial transplantation, mitoquinone, and melatonin | Increases - enhanced | myocardial function | Animal | aged IR rats | Administered intraperitoneally at the onset of reperfusion (exact dosage not specified) | Mitochondrial transplantation combined with mitoquinone and melatonin: A survival strategy against myocardial reperfusion injury in aged rats. |
| Peak serum melatonin concentrations | Decreases - are inversely correlated with | diurnal changes in pulmonary function | Human | — | Not available | Diurnal variation in asthma symptoms: Exploring the role of melatonin. |
| Peak serum melatonin concentrations | Decreases - are inversely correlated with | diurnal changes in pulmonary function | Human | — | Not available | Diurnal variation in asthma symptoms: Exploring the role of melatonin. |
| melatonin therapy | No effect - did not change significantly | cognitive function | Human | patients with dementia | Not specified | Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials.cited 77× |
| oily emulsion of docosahexaenoic acid (DHA)-phospholipids containing melatonin and tryptophan | Increases - significant improvements | several measures of cognitive function | Human | older adults with MCI | Not specified | Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment.cited 55× |
| melatonin pretreatment | Increases - restored | mitochondrial function | Molecular | H9c2 cells after A/R injury | — | Melatonin Attenuates Anoxia/Reoxygenation Injury by Inhibiting Excessive Mitophagy Through the MT2/SIRT3/FoxO3a Signaling Pathway in H9c2 Cells. |
| melatonin and insulin coadministration | Decreases - abolished many of the deleterious effects | type 1 diabetes on rat renal function | Animal | rats | — | Coadministration of Melatonin and Insulin Improves Diabetes-Induced Impairment of Rat Kidney Function. |
| Tryptophan metabolites such as 5-methoxytryptophan (5-MTP) and melatonin | Increases - protecting | mitochondrial integrity and function | Molecular | mesenchymal stromal/stem cells (MSCs) | Not specified | Control of Mesenchymal Stromal Cell Senescence by Tryptophan Metabolites.cited 18× |
| melatonin in combination with other drugs such as antibiotics, resveratrol, and anti-oxidants | Increases - showing synergistic effects in improving | cardiac function | Human | — | Not specified | Melatonin as a potential treatment for septic cardiomyopathy.cited 11× |
| long-term oral melatonin administration | Increases - improved | RGCs function | Human | patients with advanced glaucoma | Daily at 10:30 pm (specific dosage amount not provided). | Melatonin mitigates disrupted circadian rhythms, lowers intraocular pressure, and improves retinal ganglion cells function in glaucoma.cited 38× |
| combined treatment of local radiofrequency ablation (RFA) and melatonin (MLT) | Decreases - minimizing | lung function injury | HumanAnimal | early lung cancer patients with multiple pulmonary nodules | Not specified | Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development.cited 45× |
| combination of buspirone with melatonin | Increases - may benefit | cognitive function | Human | patients with MDD | Melatonin-SR 3 mg (combined with buspirone 15 mg). | Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder.cited 22× |
| melatonin and its metabolites | Increases - enhancing | mitochondrial function | Human | — | Not specified | Revisiting the role of melatonin in human melanocyte physiology: A skin context perspective. |
| melatonin and its metabolites | Increases - enhancing | mitochondrial function | Human | — | Not specified | Revisiting the role of melatonin in human melanocyte physiology: A skin context perspective. |
| Sildenafil plus Melatonin | Increases - statistically significant improvement was found | sexual function (desire and arousal) | Human | women with PCOS undergoing Metformin | Not specified in the abstract. | Improved psychosexual wellbeing with administration of combined Sildenafil plus Melatonin compared than either drug alone in management of women with polycystic ovarian syndrome: a 3-month randomized clinical study. |
| Sildenafil plus Melatonin | Increases - enhances | sexual function | Human | women with PCOS who undergoing Metformin treatment | Not specified in the abstract. | Improved psychosexual wellbeing with administration of combined Sildenafil plus Melatonin compared than either drug alone in management of women with polycystic ovarian syndrome: a 3-month randomized clinical study. |
| Sildenafil plus Melatonin | Increases - could enhance | sexual function | Human | women with PCOS who undergoing Metformin | Not specified in the abstract. | Improved psychosexual wellbeing with administration of combined Sildenafil plus Melatonin compared than either drug alone in management of women with polycystic ovarian syndrome: a 3-month randomized clinical study. |
| dopamine and melatonin receptors | No effect - formed heteromers | function impact on eye physiology | HumanMolecular | heterologous systems | — | Expression of Melatonin and Dopamine D |
| Melatonin combination therapy | Increases - provided adequate functional improvement | motor function | Animal | rats with sciatic nerve crush injury | 15-mg/kg melatonin (MEL group), 15-mg/kg methylprednisolone + 15-mg/kg melatonin (MMP group). | Melatonin and Methylprednisolone Combination Ameliorates Inflammation and Enhances Recovery After Sciatic Nerve Crush Injury. |
| cocktails of supplements including melatonin | Increases - associated with recovery | lost motor function | Human | — | Not specified. | ALSUntangled #61: melatonin.cited 2× |